"Receptors, sigma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of cell surface receptors recognized by its pharmacological profile. Sigma receptors were originally considered to be opioid receptors because they bind certain synthetic opioids. However they also interact with a variety of other psychoactive drugs, and their endogenous ligand is not known (although they can react to certain endogenous steroids). Sigma receptors are found in the immune, endocrine, and nervous systems, and in some peripheral tissues.
Descriptor ID |
D017480
|
MeSH Number(s) |
D12.776.543.750.695.620.775 D12.776.543.750.720.600.610.775 D12.776.543.750.750.555.610.775
|
Concept/Terms |
Receptors, sigma- Receptors, sigma
- sigma Receptors
- Receptors, sigma Opioid
- Opioid Receptors, sigma
- sigma Opioid Receptors
- Receptors, Opioid, sigma
- sigma Receptor
- Receptor, sigma
|
Below are MeSH descriptors whose meaning is more general than "Receptors, sigma".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Opioid [D12.776.543.750.695.620]
- Receptors, sigma [D12.776.543.750.695.620.775]
- Receptors, Neurotransmitter [D12.776.543.750.720]
- Receptors, Neuropeptide [D12.776.543.750.720.600]
- Receptors, Opioid [D12.776.543.750.720.600.610]
- Receptors, sigma [D12.776.543.750.720.600.610.775]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Neuropeptide [D12.776.543.750.750.555]
- Receptors, Opioid [D12.776.543.750.750.555.610]
- Receptors, sigma [D12.776.543.750.750.555.610.775]
Below are MeSH descriptors whose meaning is more specific than "Receptors, sigma".
This graph shows the total number of publications written about "Receptors, sigma" by people in this website by year, and whether "Receptors, sigma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2018 | 2 | 0 | 2 |
2020 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, sigma" by people in Profiles.
-
Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy. Expert Opin Ther Targets. 2021 06; 25(6):435-449.
-
Homozygosity for rs17775810 Minor Allele Associated With Reduced Mortality of COVID-19 in the UK Biobank Cohort. In Vivo. 2021 Mar-Apr; 35(2):965-968.
-
Observational study of haloperidol in hospitalized patients with COVID-19. PLoS One. 2021; 16(2):e0247122.
-
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci. 2021 Mar; 271(2):249-258.
-
Novel Sigma 1 Receptor Antagonists as Potential Therapeutics for Pain Management. J Med Chem. 2021 01 14; 64(1):890-904.
-
Identification of antiviral antihistamines for COVID-19 repurposing. Biochem Biophys Res Commun. 2021 01 29; 538:173-179.
-
Reissuing the sigma receptors for SARS-CoV-2. J Clin Neurosci. 2020 10; 80:72-73.
-
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 07; 583(7816):459-468.
-
Systolic blood pressure as a potential target of sigma-1 receptor agonist therapy. J Clin Hypertens (Greenwich). 2018 02; 20(2):416-417.
-
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. Neurotherapeutics. 2018 01; 15(1):178-189.